Adaptimmune Therapeutics Plc - ADAP STOCK NEWS

The gene therapy market is projected to grow by $4.61 billion from 2023 to 2027, with a CAGR of 19.91%. This growth is attributed to increasing special drug designations, benefits of gene therapy, and rising chronic diseases prevalence.

The market report analyzes key areas including market size, trends, growth drivers, and challenges, covering around 25 vendors. The report segments the market by therapy areas like oncology, CNS, and rare diseases, along with delivery modes and geography.

Key vendors include Adaptimmune Therapeutics (ADAP) and Orchard Therapeutics (ORTX), among others.

The report titled "Global TCR Therapy Market, 2022-2035" outlines significant growth prospects in TCR-based therapies, with an annual growth rate of 51% expected over the next decade. This emerging class of adoptive therapy targets specific tumor markers using genetically modified T-cells, showing efficacy primarily in hematological and solid tumors. The FDA's approval of Kimmtrak for treating metastatic uveal melanoma in January 2022 marks a milestone in the market. The market is projected to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma, with over 90% of therapy candidates being autologous.

ReCode Therapeutics has established a scientific advisory board (SAB) to enhance its genetic medicine pipeline, led by Daniel J. Siegwart. The SAB includes experts such as Rafael Amado and Carrolee Barlow, who bring extensive experience in drug development and delivery technology. This initiative aims to advance their selective organ targeting (SORT) lipid nanoparticle platform and accelerate programs for conditions like primary ciliary dyskinesia and cystic fibrosis to enter clinical stages in 2023.

Alnylam Pharmaceuticals has appointed Dr. Elliott Sigal to its Board of Directors, enhancing its leadership at a pivotal moment. With decades of experience, including his role as Chief Scientific Officer at Bristol-Myers Squibb, Dr. Sigal contributed to the launch of 14 new medicines across various therapeutic areas. His expertise is expected to strengthen Alnylam's ongoing efforts in advancing RNAi therapeutics aimed at rare diseases. The company continues its pursuit of transforming healthcare through innovative treatments, guided by its 'Alnylam P5x25' strategy.

Adaptimmune Therapeutics (ADAP) presented promising preclinical evidence for its next-gen SPEAR T-cells (ADP-A2M4N7X19) and engineered TILs (ADP-TILIL7) at the ASGCT annual meeting. The SPEAR T-cells are designed to enhance treatment durability and immune response in solid tumors by secreting IL-7 and CCL19. The company plans to initiate Phase 1 trials for both therapies targeting various solid tumors and metastatic melanoma, respectively. These advancements suggest improved potential for cancer treatment, building on results from Adaptimmune's earlier T-cell therapies.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported financial results for Q1 2022, highlighting a revenue increase to $3.6 million from $0.4 million year-over-year, attributed to heightened development activities. However, R&D expenses rose to $36.8 million from $24.5 million, and G&A expenses increased to $16.8 million compared to $13.8 million in Q1 2021. The net loss was $50.3 million, up from $37.8 million. The company remains funded into early 2024 and will present data on its therapies at upcoming conferences, including ASCO and ASGCT.

Adaptimmune Therapeutics (Nasdaq: ADAP) has appointed Dr. Joanna Brewer as Chief Scientific Officer (CSO) effective immediately. Dr. Brewer, who previously served as Senior Vice President of Allogeneic Research, has a robust background in cell therapy and has been instrumental in developing the company’s iPSC-derived T-cell therapies. This role aims to enhance Adaptimmune's scientific research and advance its pipeline of cancer immunotherapies, positioning the company for continued innovation in the treatment of various cancers.

Adaptimmune Therapeutics (Nasdaq: ADAP) will announce its financial results for Q1 2022 on May 9, 2022, before US market opening. The company specializes in cancer immunotherapy and utilizes its SPEAR® T-cell platform to develop innovative treatments. Following the earnings release, a live teleconference and webcast will be held at 8:00 a.m. EDT. Interested parties can access the webcast via the company’s investor website. The PR emphasizes the company's commitment to advancing its TCR therapeutic candidates, while cautioning about the inherent risks and uncertainties in clinical development.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) presented significant findings at the AACR annual meeting regarding its MAGE-A4-targeting SPEAR T-cell therapies. The data confirms MAGE-A4 as a viable target for multiple solid tumors, with a 67% eligibility rate in synovial sarcoma and 20%-35% across other cancers such as lung and bladder. Out of 6167 patients screened, 2729 were eligible, highlighting a robust patient pool for ongoing trials. These results build upon prior data, emphasizing Adaptimmune's commitment to advancing cancer treatment options.